52 results
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals, Inc.
9 Aug 24
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
7:13am
to be designated as a small to medium sized enterprise (or SME) in Europe which provides for certain benefits including fee reductions and other support from
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals, Inc.
15 May 24
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
7:13am
benefits including to prevent recurrence of CDI.
Additional data from exploratory endpoints will provide further favorable separation between these two … for certain benefits including fee reductions and other support from the EMA for seeking a Marketing Authorization for Europe.
We attended
FWP
ACXP
Acurx Pharmaceuticals, Inc.
2 Apr 24
Free writing prospectus
7:31am
benefits, competitive position, business strategies, objectives of mana gem ent, potential growth opportunities, potential market size, possible or assumed
8-K
EX-99.1
x747j
18 Mar 24
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
4:15pm
8-K
EX-1.1
x0cph p6qbr87b
15 Nov 23
Entry into a Material Definitive Agreement
5:02pm
424B5
urbq3
15 Nov 23
Prospectus supplement for primary offering
4:49pm
424B5
q3k4eo0g16cqrieju4
17 May 23
Prospectus supplement for primary offering
4:25pm
8-K
EX-10.1
rgddn4
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm
8-K
EX-1.1
11mu571dfoz
17 May 23
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
4:19pm